Holen Sie sich die Stockscreener-App
3.65
0.54%
-0.02
Molecular Partners Ag Adr Aktie (MOLN) Neueste Nachrichten
Molecular Partners AG (MOLN) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
Molecular Partners AG (MOLN) Key Financial Ratios – Valuation, Profitability & More - Value Research
Molecular Partners AG (MOLN) Financials – Balance Sheet, Profit & Loss, Cash Flow - Value Research
MOLN Q2 2026 Earnings: Reported Loss of -$0.35 per ADS, No Revenue, Shares Slip 3.28% - careplusvn.com
MOLN Q2 2026 Earnings: Reported Loss of -$0.35 per ADS, No Revenue, Shares Slip 3.28%Surprise Factor Analysis - dars.gov.et
Nyxoah SA (NYXH) Stock Price & News - Syfe
Molecular Partners AG (MOLN) Peer Comparison – Compare with Others - Value Research
Why Does Molecular Partners (NASDAQ:MOLN) Update Matter Today? - Kalkine Media
Molecular (MOLN) Latest Quarter: EPS Beats Its Estimate in the Latest Reading; Price Move: Shares Move 4.02% Higher in the Latest ReadingSurprise Factor Analysis - careplusvn.com
Molecular (MOLN) Latest Quarter: EPS Beats Its Estimate in the Latest Reading; Price Move - dars.gov.et
Molecular (MOLN) Latest Quarter: EPS Beats Its Estimate in the Latest Reading; Price Move: Shares Move 4.02% Higher in the Latest ReadingEarnings Weakness Phase - dars.gov.et
Molecular (MOLN) Latest Quarter: EPS Beats Its Estimate in the Latest Reading; Price Move: Shares Move 4.02% Higher in the Latest ReadingGuidance Revision Trend - dars.gov.et
Molecular (MOLN) Outlook: Adds 3.55% to Close at $4.38 on the Day; Key Range: the Supplied Trading Band Runs From $4.16 to $4.60 on the DayETF AUM Growth - dars.gov.et
Molecular (MOLN) Results Breakdown: The Available Earnings Metric Delivers a Beat in the Current Update; Post-Report: The Share Price Adds 0.93%New Analyst Coverage - careplusvn.com
Molecular (MOLN) Results Breakdown: The Available Earnings Metric Delivers a Beat in the Current Update; Post-Report: The Share Price Adds 0.93%EPS Growth Rate - dars.gov.et
Molecular (MOLN) Results Breakdown: The Available Earnings Metric Delivers a Beat in the Current Update; Post-Report: The Share Price Adds 0.93%Consensus Forecast Report - dars.gov.et
Molecular (MOLN) Results Breakdown: The Available Earnings Metric Delivers a Beat in the Current Update; Post-Report: The Share Price Adds 0.93%Share Repurchase Impact - dars.gov.et
Molecular (MOLN) Results Breakdown: The Available Earnings Metric Delivers a Beat in the Current Update; Post-Report: The Share Price Adds 0.93%Slow Growth Warning - dars.gov.et
Molecular Partners (NASDAQ:MOLN) Shares Up 6.4%Still a Buy? - MarketBeat
MOLN Holds Steady at $3.93 as Molecular Partners Consolidates Within RangeTriple Bottom - careplusvn.com
Molecular Partners reports progress in MP0317 clinical trial - grafa.com
MOLN Q4 2025 Earnings: Narrowed Loss Beats Estimates as Stock Declines MarginallyRevenue Growth Outlook - dars.gov.et
MOLN Q4 2025 Earnings: Narrowed Loss Beats Estimates as Stock Declines MarginallyOperating Margin Analysis - dars.gov.et
H.C. Wainwright reiterates Molecular Partners stock rating on trial progress By Investing.com - Investing.com Nigeria
Molecular Partners advances MP0712 cancer trial - grafa.com
H.C. Wainwright reiterates Molecular Partners stock rating on trial progress - Investing.com
Molecular Partners and Orano Med dose first patients in MP0712 trial - scanx.trade
6ML0 Forecast — Price Target — Prediction for 2027 - TradingView
A3CSB5 Forecast — Price Target — Prediction for 2027 - TradingView
A3CSB5 Forecast — Price Target — Prediction for 2027 - TradingView
6ML0 Forecast — Price Target — Prediction for 2027 - TradingView
6ML0 Forecast — Price Target — Prediction for 2027 - TradingView
6ML0 Forecast — Price Target — Prediction for 2027 - TradingView
6ML0 Forecast — Price Target — Prediction for 2027 - TradingView
EU Eases Deportation Rules as Labor Shortages Threaten GDP And Unrest Fuels Political Pressure - Sahm
EU Eases Deportation Rules as Labor Shortages Threaten GDP And Unrest Fuels Political PressureNovartis - Benzinga
Molecular Partners to Present at TD Cowen’s 7th Annual Oncology Innovation Summit - GlobeNewswire Inc.
MOLN - Finviz
Molecular Partners Reports Financial Results and Highlights for Q1 2026, with Clinical Studies Initiated on MP0712 and MP0317 - GlobeNewswire Inc.
Molecular Partners to hold oral presentations on DLL3-targeting Radio-DARPin candidate MP0712 at multiple upcoming scientific conferences - GlobeNewswire Inc.
Molecular Partners reports phase 1 data for cancer drug MP0317 By Investing.com - Investing.com Australia
Molecular Partners reports phase 1 data for cancer drug MP0317 - Investing.com
Molecular Partners publishes Phase 1 MP0317 data in Nature Cancer demonstrating tumor-localized CD40 activation and tumor microenvironment remodeling - GlobeNewswire Inc.
Molecular Partners AG Sponsored ADR (NASDAQ:MOLN) Short Interest Down 20.4% in April - MarketBeat
Head & ShouldersStock ScreenerCharts - Finviz
Molecular Partners (NASDAQ:MOLN) Given "Buy" Rating at HC Wainwright - MarketBeat
H.C. Wainwright reiterates Molecular Partners stock rating at buy - Investing.com
H.C. Wainwright reiterates Molecular Partners stock rating at buy By Investing.com - Investing.com South Africa
Molecular Partners (NASDAQ:MOLN) Stock Price Up 5%Still a Buy? - MarketBeat
Molecular Partners Announces all Board Proposals Approved, Clare Fisher Elected as New Board Member at Annual General Meeting - GlobeNewswire Inc.
1.49%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):